OPRM1

protein-coding

opioid receptor mu 1, the group of Opioid receptors

Gene summary

This gene encodes one of at least three opioid receptors in humans; the mu opioid receptor (MOR). The MOR is the principal target of endogenous opioid peptides and opioid analgesic agents such as beta-endorphin and enkephalins. The MOR also has an important role in dependence to other drugs of abuse, such as nicotine, cocaine, and alcohol via its modulation of the dopamine system. The NM_001008503.2:c.118A>G allele has been associated with opioid and alcohol addiction and variations in pain sensitivity but evidence for it having a causal role is conflicting. Multiple transcript variants encoding different isoforms have been found for this gene. Though the canonical MOR belongs to the superfamily of 7-transmembrane-spanning G-protein-coupled receptors some isoforms of this gene have only 6 transmembrane domains. [provided by RefSeq, Oct 2013]

MANE transcript

NM_000914.5

Inheritance

—

ClinVar variants

U:111B:8

Top phenotype

Tramadol response

gnomAD constraint

pLI —, LoF o/e 0.87

Max pathogenic AF

—

Genomic locus

chr6:154,010,496-154,246,867

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~236.4 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

No GenCC data available for this gene.

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to OPRM1 variants in ClinVar

3 Conditions Cataloged
Tramadol responseTotal: 324
not specifiedTotal: 56
not providedTotal: 8

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_000914.5. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
12
clinvar
2
clinvar
1
clinvar
15
missense
85
clinvar
4
clinvar
1
clinvar
90
nonsense
6
clinvar
6
start loss
0
frameshift
7
clinvar
7
splice donor/acceptor (+/-2bp)
1
clinvar
1
Total0011162119
Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 46 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_000914.5RefSeqNP_000905.34MANE Select
ENST00000330432.12EnsemblENSP00000328264.74MANE Select
NM_001008503.3RefSeqNP_001008503.24Standard
NM_001008504.4RefSeqNP_001008504.23Standard

Model Organisms & Knockout Phenotypes

Observed phenotypic effects in mouse and zebrafish models

Gene / ModelOrganismObserved Phenotype
oprm1Danio rerio

Structure: optic tectum

Quality: increased process quality

abnormal

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Estrogen signaling pathway - Homo sapiens (human)
  • Neuroactive ligand-receptor interaction - Homo sapiens (human)
  • Morphine addiction - Homo sapiens (human)
  • Levomethadyl Acetate Action Action Pathway
  • Fluoxetine Action Pathway

Biological Process

  • acute inflammatory response to antigenic stimulus
  • G protein-coupled receptor signaling pathway
  • G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
  • adenylate cyclase-activating dopamine receptor signaling pathway
  • negative regulation of adenylate cyclase activity

Molecular Function

  • G-protein alpha-subunit binding
  • G protein-coupled receptor activity
  • beta-endorphin receptor activity
  • voltage-gated calcium channel activity
  • protein binding

Cellular Component

  • endosome
  • endoplasmic reticulum
  • Golgi apparatus
  • plasma membrane
  • integral component of plasma membrane

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000434900
Coding exons
5
Length
236371
Individuals with no LoFs
125016
Homozygous LoFs
1
Heterozygous LoFs
200
Defined
125217
p
0.000803
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense-0.6193112821.100.00001423202
Missense (PolyPhen)119104.161.14251277
Synonymous-0.4911171101.060.000005611010
Loss of Function0.5261719.50.8710.00000122186

Population LoF Frequency

PopulationCAFp-valueStatus
African0.000780.00076rare
Latino/Admixed American0.000520.00052rare
Ashkenazi Jewish0.00180.0017notable
East Asian00.0absent
Finnish0.000610.00060rare
European (Non-Finnish)0.000270.00026rare
South Asian0.00360.0035notable
Other0.000500.00049rare

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:7905839, PubMed:7957926, PubMed:7891175, PubMed:12589820, PubMed:9689128). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF- kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta- arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta- arrestins. The activation of the ERK pathway occurs either in a G- protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects (PubMed:20525224). Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity (PubMed:16580639). {ECO:0000250|UniProtKB:P33535, ECO:0000250|UniProtKB:P42866, ECO:0000269|PubMed:10529478, ECO:0000269|PubMed:12068084, ECO:0000269|PubMed:12589820, ECO:0000269|PubMed:16580639, ECO:0000269|PubMed:20525224, ECO:0000269|PubMed:7891175, ECO:0000269|PubMed:7905839, ECO:0000269|PubMed:7957926, ECO:0000269|PubMed:9689128, ECO:0000303|PubMed:10836142, ECO:0000303|PubMed:19300905}.;

Recessive Scores

pRec
0.280

Intolerance Scores

LoFtool
0.936
RVIS EVS
1.91
RVIS percentile EVS
97.43

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
0.654

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.